Safety and Efficacy of SM17 in Healthy Volunteers
Author Information
Author(s): Xu Guolin, Paglialunga Sabina, Qian Xuchen, Ding Ru, Webster Kenneth, van Haarst Aernout, Engel Caroline, Hui Chin Wai, Lam Lik Hang, Li Weimin, Wu Wai Chung, Rasmussen Scott, Hunt Allen, Leung Shui-on
Primary Institution: SinoMab BioScience Limited, Hong Kong, Hong Kong SAR, China
Hypothesis
Can SM17, a novel monoclonal antibody targeting IL-17RB, effectively treat allergic asthma by blocking IL-25 signaling?
Conclusion
SM17 is well tolerated and shows potential as a therapeutic agent for allergic asthma.
Supporting Evidence
- SM17 significantly suppressed Th2 inflammation in pre-clinical models.
- No drug-related serious adverse events were observed in the clinical trial.
- Total SM17 exposure increased in a dose-proportional manner.
- Mean accumulation ratios confirmed moderate accumulation of SM17.
- SM17 treatment normalized lung pathology in animal models of asthma.
Takeaway
Researchers tested a new medicine called SM17 to see if it could help people with asthma. They found it was safe and might work well.
Methodology
The study involved a two-part clinical trial with healthy adults receiving varying doses of SM17 or placebo, assessing safety, pharmacokinetics, and pharmacodynamics.
Potential Biases
Potential bias due to funding from SinoMab BioScience Limited.
Limitations
The study was conducted only in healthy volunteers, and the efficacy in asthma patients remains to be evaluated.
Participant Demographics
77 healthy adults aged 19 to 55, with a mix of males and females, and various ethnic backgrounds.
Statistical Information
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website